Company: ARTL
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0001640334-25-000335
Chunk: 31

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1
Chunk 31
---
 third parties, we could lose license rights that are vital to our business.    ·Changes in regulatory requirements or other unforeseen circumstances may impact the timing of the initiation or completion of our clinical trials.    ·We face many of the risks and difficulties frequently encountered by relatively new companies with respect to our operations.    ·The Company has no mature product candidates and may not be successful in licensing any.    ·Even if the Company is successful in licensing lead product candidates, resource limitations may limit our ability to successfully develop them.

Risks Related to our Intellectual Property:

 ·If we are unable to obtain and maintain patent protection for our products, our competitors could develop and commercialize products and technology similar or identical to our product candidates, and our ability to successfully commercialize any product candidates we may develop, and our science may be adversely affected.    ·Obtaining and maintaining our patent protection depends on compliance with various procedural measures, document submissions, fee payments and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.    ·We may be subject to claims challenging the inventorship of our patents and other intellectual property.    ·Intellectual property rights do not necessarily address all potential threats.    ·Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.

 21Table of contents

Risks Related to our Securities:

 ·Our Common Stock may be delisted from The Nasdaq Capital Market if the Company cannot maintain compliance with Nasdaq’s continued listing requirements.    ·If we sell securities in future financings stockholders may experience immediate dilution and, as a result, our stock price may decline.    ·The price of our securities may be volatile, and you could lose all or part of your investment. Further, we do not know whether an active, liquid and orderly trading market will continue for our securities or what the market price of our securities will be and as a result it may be difficult for you to sell your shares of our securities.    ·Shares of our Common Stock that have not been registered under federal securities laws are subject to resale restrictions imposed by Rule 144, including those set forth in Rule 144(i) which apply to a former “shell company.”    ·Sales of our currently issued and outstanding stock may become freely tradable pursuant to Rule 144 and sales of such shares may have a depressive effect on the share price of its Common Stock.